Published in final edited form as:

J Am Chem Soc. 2009 January 21; 131(2): 563–569. doi:10.1021/ja806092w.

Cryptophane Xenon-129 Nuclear Magnetic Resonance Biosensors Targeting Human Carbonic Anhydrase

Jennifer M. Chambers, P. Aru Hill, Julie A. Aaron, Zhaohui Han, David W. Christianson, Nicholas N. Kuzma, and Ivan J. Dmochowski*

Contribution from the Department of Chemistry, University of Pennsylvania, Department of Biomedical Engineering, University of Rochester

Abstract

^{129}Xe NMR biosensors are promising agents for the early detection of diseases, given that biomolecular interactions can perturb ^{129}Xe chemical shifts well beyond the typical field inhomogeneity of clinical MRI. We introduce human carbonic anhydrase (CA) as a single-binding-site enzyme for studying xenon biosensor-protein interactions. A xenon-binding cryptophane was substituted with linkers of varying lengths to *p*-benzenesulfonamide to yield non-diastereomeric biosensors with a single ^{129}Xe NMR resonance. X-ray crystallography confirmed binding of the 8-bond-linked biosensor containing a single xenon atom in the CAII active site. Biosensor dissociation constants ($K_d = 20\text{--}110\text{ nM}$) were determined by isothermal titration calorimetry (ITC) for isozymes CA I and II. The biosensor-CA complexes yielded “bound” hyperpolarized ^{129}Xe NMR resonances of narrow linewidth that were shifted by 3.0 to 7.5 ppm downfield, signifying much larger shifts than seen previously. Moreover, isozyme-specific chemical shifts clearly differentiated CA I and II, despite their similar active-site architectures. Thus, xenon biosensors may provide a powerful strategy for diagnosing human diseases characterized by the upregulation of specific CA isozymes and other protein biomarkers.

Introduction

Magnetic resonance imaging (MRI) is used widely (~40 million procedures annually) to scan deep tissues in human patients with high spatial resolution. Intrinsic ^1H MRI signals from water and fat provide low sensitivity, thus contrast is typically enhanced using gadolinium- or iron-oxide-based agents.^{1,2} However, there have been challenges in developing these contrast agents for in vivo imaging of medically relevant biomarkers, such as proteins. Moreover, U.S. and European agencies have recently issued advisories based on studies showing that gadolinium agents pose risks in patients with impaired renal function for developing nephrogenic systemic sclerosis/dermatosis (NSF/NSD).³ These findings motivate the investigation of non-proton-based, hyperpolarized MRI agents such as ^{129}Xe , ^{13}C , and ^3He , which enable physiological assays, for example of blood flow and lung function, and provide sensitive methods for studying proteins and metabolites.^{4–6}

Functional xenon biosensors have attracted recent attention due to their potential for simultaneously detecting multiple frequency-resolved ^{129}Xe resonances associated with medically relevant biomarkers.^{7,8} Monatomic xenon-129 is spin-1/2 and exhibits a large chemical shift window (~300 ppm),⁹ while laser polarization enhances ^{129}Xe NMR signals more than 10,000-fold,¹⁰ which helps to compensate for a weaker magnetic moment and much lower concentration of hyperpolarized ^{129}Xe compared to ^1H in aqueous solutions. Since the

first report of hyperpolarized ^{129}Xe MRI in excised mouse organs,¹¹ numerous advances in biological imaging with this agent have been made.¹² In a recent study, the xenon gas exchange kinetics of frequency-resolved tissue barrier and red blood cell resonances were measured and used to detect regions of rat lung injury.¹³ Frequency-resolved MRI of an immobilized xenon biosensor has also been demonstrated,¹⁴ showing the promise of imaging biosensors bound to a target macromolecule. Most recently, we showed that peptide-functionalized cryptophanes can be delivered to human cells and achieve intracellular concentrations ($\geq 100\ \mu\text{M}$) that should allow in vivo hyperpolarized ^{129}Xe MRI studies.¹⁵

Herein, we systematically varied the interaction of a xenon biosensor with a biomedically relevant protein, human carbonic anhydrase (CA), in order to investigate whether small changes in binding are detectable by ^{129}Xe NMR. Cryptophane-A-based xenon biosensors offer the possibility of tuning the frequency of the bound ^{129}Xe nucleus, through electronic and mechanical perturbations of the cage environment. Water-soluble cryptophane-A derivatives have been shown to bind xenon with micromolar dissociation constants under nearly physiological conditions, such as in blood plasma.¹⁶ Functionalizing the cryptophane with a biological recognition motif creates a biosensor for the detection of specific proteins, such as matrix metalloproteinases known to be secreted by various tumor cells.¹⁷ Current strategies for constructing protein-targeted xenon biosensors are (i) the use of a peptide to solubilize the large ($\sim 1\ \text{kD}$) nonpolar cryptophane,^{7,8,18} or (ii) the incorporation of cryptophanes into supramolecular dendrimers.¹⁹ While the use of polyamidoamine (PAMAM) dendrimers affords narrow ^{129}Xe linewidths, it also shields the cryptophane from solution, and renders the bound ^{129}Xe relatively insensitive to protein binding. In contrast, studies with peptido-biotin cryptophane biosensors have shown that decreasing the linker length to the biotin ligand increases the change in chemical shift but also broadens the linewidth upon avidin binding.¹⁸ Attaching a peptide to the chiral cryptophane creates diastereomers, which increases the number of peaks in the ^{129}Xe spectrum, and correspondingly decreases the signal-to-noise. Computational studies have helped to assign the various NMR resonances to their respective diastereomers.²⁰ However, the tetrameric nature of avidin can further complicate the ^{129}Xe NMR spectrum.¹⁸

In the current study, carbonic anhydrase was chosen as the target enzyme due to its biomedical relevance and status as a model system for understanding protein-ligand interactions.²¹ CA is involved in many physiological processes such as carbon dioxide transport and pH homeostasis in tissue.²² However, some CAs also appear to have detrimental effects on human health: For example, CA I, II and other isozymes, were shown to be present and probably involved in the formation of certain tumors and polycystic kidney disease.^{23, 24} Thus, the development of isozyme-specific CA biosensors holds considerable promise for cancer imaging.

Numerous crystal structures of CA-inhibitor complexes are available to guide biosensor development, and CAII in particular has served as a successful model system for rational drug design.^{21,25,26} CA is a monomeric protein, which reduces the probability of biosensor-biosensor interactions, which were problematic with the tetrameric avidin target.¹⁸ Water-soluble biosensors for CA were developed that avoid the appendage of additional stereocenters to the cryptophane core. Use of the arylsulfonamide ligand allows comparison of the biosensor-CA interaction with other designed CA inhibitors. Solution-based assays for CA can confirm active-site binding, and identify protein-biosensor complexes suitable for crystallization.^{27, 28} We recently reported the crystal structure of CAII bound to a benzenesulfonamide-linked-cryptophane (Figure 1).²⁹

Experimental Procedures

Chemical synthesis

Synthetic protocols and characterization of all new compounds shown in Scheme 1 can be found in Supporting Information (Synthetic Methods and Figure S1).

To conjugate the sulfonamide linker to the tripropargyl cryptophane-A cage, 45 – 90 mg of **1** was dissolved in 2.0 – 4.0 mL dry DMSO at rt with stirring. Sulfonamide linker **2**, **3**, or **4** (1.1 eq) was added. A 100 mM CuSO₄ solution (0.25 eq) was added, followed by 2,6-lutidine (0.25 eq), and 300 mM (+)-sodium-L-ascorbate (0.75 eq). The reaction was allowed to stir overnight and then poured into 50 mL H₂O. This solution was extracted with ethyl acetate and the combined organic layer was washed with saturated NaCl solution, dried over Na₂SO₄, filtered, and evaporated. The yellow oil recovered was purified by silica gel column chromatography to give the pure product as a white solid.

Compound **6**, **7**, or **8** (27.2 – 54.2 mg) was dissolved in 2.0 mL dry DMSO at rt with stirring. **5** (10 eq) was added. A 100 mM CuSO₄ solution (0.25 eq) was added, followed by 2,6-lutidine (0.25 eq), and 300 mM (+)-sodium-L-ascorbate (0.75 eq). The reaction was allowed to stir overnight and then poured into 30 mL H₂O. Compound **6**, **7**, or **8** was dissolved in dry DMSO at rt with stirring. Solubilizing linker **5** was introduced. A 100 mM CuSO₄ solution (0.25 eq) was added, followed by 2,6-lutidine (0.75 eq), and 300 mM (+)-sodium-L-ascorbate (0.25 eq). The reaction was allowed to stir overnight and then poured into H₂O. This solution was extracted with ethyl acetate and the combined organic layer was washed with saturated NaCl solution, dried over Na₂SO₄, filtered, and evaporated. The yellow oil recovered was dissolved in minimal 1 M NaOH and a white solid was precipitated with the addition of 1 M HCl. The liquid was decanted after a 5-min centrifugation at 13.2 krpm. The solid was then redissolved in minimal 1 M NaOH, precipitated with 1 M HCl, and isolated. The solid was then sonicated for 10 min in DI H₂O and dried under vacuum. If impurities remained, solid was dissolved in minimal CH₂Cl₂ and precipitated with diethyl ether until desired purity was achieved. Pure product was recovered as a white solid.

Isothermal titration calorimetry (ITC)

All calorimetry experiments were conducted at 298 K on a VP-ITC titration microcalorimeter from MicroCal, Inc. (Northampton MA), following standard protocols and data analysis.^{30, 31}

CA I and II were exhaustively dialyzed against 50 mM Tris-SO₄ (pH = 8.0). Compounds (~10 mM stock solution in DMSO) were dissolved at a concentration of 135 to 300 μM in an aliquot of the same buffer, and an equivalent volume of DMSO was added to the enzyme solution. Prior to the titration experiment, samples were degassed under vacuum for 5 min. The sample cell (effective volume 1.4 mL) was overfilled with 1.8 mL of CA at a concentration of 14 to 26 μM and the reference cell was filled with water. The contents of the sample cell were titrated with 30 aliquots (10 μL each) of inhibitor (two initial 2 μL injections were made, but not used in data analysis). After each injection, the heat change was measured and converted to the corresponding enthalpy value. The reaction mixture was continuously stirred at 300 rpm during titration. Control experiments were carried out by titrating the inhibitor into the buffer solution under identical experimental conditions. The calorimetric data are presented with the background titrations subtracted from the experimental data. The amount of heat produced per injection was calculated by integration of the area under each peak. Data were fit to the equation $q = V\Delta H[E]_t K[L]/(1 + K[L])$, where q is the heat evolved during the course of the reaction, V is the cell volume, ΔH is the binding enthalpy per mole of ligand, $[E]_t$ is the total enzyme concentration, K is the binding constant, and $[L]$ is inhibitor concentration. Nonlinear

regression fitting to the binding isotherm (ORIGIN 5.0 software, MicroCal) using a one-site model gave the equilibrium dissociation constant of the ligand, K_d , and estimates of the standard error, as provided in Table 1. The error is $\sigma_i = \sqrt{(C_{ii}\chi^2)}$, where C_{ii} is the diagonal element of the variance-covariance matrix.

Hyperpolarized ^{129}Xe NMR spectroscopy

Isotopically enriched xenon (86% ^{129}Xe and 0.13% ^{131}Xe , Spectra Gases) was polarized via spin-exchange optical pumping with rubidium at 175 °C³² and cryogenically separated³³ from the buffer-gas mixture (1% Xe, 10% N₂, 89% He by volume) in a Nycomed-Amersham (now GE) IGI.Xe.2000 gas-flow polarizer (output ^{129}Xe polarization 10–20% for 300-mL batches of pure xenon gas). Immediately after thawing, xenon was transferred to a special aluminum container inside a home-built ^{129}Xe probe in the bore of a 9.4 T superconducting magnet (Oxford Instruments). Spin relaxation time T_1 of ^{129}Xe gas in the container ranged from 70 to 120 min.

Hyperpolarized ^{129}Xe NMR measurements¹² with water-soluble cryptophane biosensors were performed similarly to our previous studies,¹⁷ with the exception of frequency-shift referencing described below. For experiments not involving CA, 650 μL solutions of **C6B** (96 μM), **C7B** (186 μM), or **C8B** (121 μM) in 50 mM Tris-SO₄ water-based buffer (pH = 8.0) were added to a 5-mm NMR tube fitted vertically onto a removable probe. A 1-mm outer diameter glass capillary was inserted into the NMR tube to allow bubbling of hyperpolarized Xe gas through the sample. NMR samples were interchanged without removing the hyperpolarized Xe container from the vertical magnet bore.

After thermal equilibrium inside the magnet had been achieved (temperature range for all experiments was 20.0–20.5 °C, with thermal fluctuation of only 0.1 °C), hyperpolarized Xe gas was bubbled through the biosensor solution for ~1 min, and the ^{129}Xe @cryptophane signal was monitored via a 1–5 μs pulse every 10 sec. Once the ^{129}Xe @cryptophane signal indicated saturation, Xe bubbling was stopped, and four pulses at 7–11 μs were used to obtain data ($n = 4$, ^{129}Xe frequency $f_0 = 110.74668$ MHz, 40°–70° tipping pulse) and then averaged. Raw free induction decay (FID) signals were recorded in quadrature. Where useful, multiple processed spectra were averaged to increase signal-to-noise. The biosensor-CA samples were prepared in 50 mM Tris-SO₄ buffer (pH = 8.0) using the following concentrations: **C6B** (188 μM) + CAI (141 μM), **C6B** (148 μM) + CAII (123 μM), **C7B** (136 μM) + CAI (100 μM), **C7B** (132 μM) + CAII (105 μM), **C8B** (189 μM) + CAI (141 μM), **C8B** (189 μM) + CAII (153 μM). The biosensor-CA samples were then subjected to the same data collection procedure as the unbound biosensor samples. NMR data were processed using standard fast Fourier transform combined with baseline and phase corrections. Spectra were fitted to linear combinations of Lorentzians using IGOR Pro 5.0 (Wavemetrics, Inc., Oregon). Gaussian broadening of 20 Hz was applied to obtain the shown spectra, however the fits were done without any broadening.

A new procedure, detailed in the Supporting Information (^{129}Xe NMR Methods), was used to reference NMR frequencies to the ^{129}Xe gas line. In the low-frequency region, two narrow ^{129}Xe peaks (from the gas in the vertical capillary and in the spherical bubbles) were observed, superimposed on a broad peak from the gas above the liquid surface. Upon stoppage of bubbling, the down-frequency peak from the bubbles disappeared, and all other peaks shifted by –31 Hz (–0.3 ppm). The narrow gas peaks were split diamagnetically by 343 ± 20 Hz (3.1 ± 0.2 ppm), consistent with $-(s_{\text{cyl}} - s_{\text{sph}})\chi_w = 3.01$ ppm, where $s_{\text{cyl}} = 1$ and $s_{\text{sph}} = 2/3$ are magnetization shape factors for a vertical cylinder and a sphere, and χ_w is diamagnetic susceptibility of the surrounding solution based on water (–9.04 ppm in SI units). Because the chemical shift of ^{129}Xe gas at 20 °C and 1 atm is 0.509 ppm relative to ^{129}Xe gas at 0 atm,³⁴ we used the following expression to convert peak frequencies f to ppm: $\sigma[\text{ppm}] = 10^6(f - f_c + 343)/f_0 + 0.509$, where f_c is the measured peak frequency of ^{129}Xe gas in the capillary and

f_0 is the spectrometer frequency, both in Hz. The uncertainties in ^{129}Xe chemical shifts from peak fits were small (~ 4 Hz, 0.04 ppm), with additional sources of error (such as the fit to the gas reference peak) being less than the linewidths of approximately 20 Hz or more. These contributions resulted in peak uncertainties of approximately ± 0.07 ppm. ^{129}Xe chemical shifts are reported to a precision of ± 0.1 ppm. The calculated ^{129}Xe NMR chemical shifts for biosensor **C7B** were decreased by 0.1 ppm to compensate for the slightly higher temperatures (20.3–20.46 °C, see Table S1) at which these data were collected, using the measured temperature dependence of 0.28 ppm/°C.¹⁸

Results

Biosensor design and synthesis

Unlike prior biotin-functionalized Xe biosensors, which gained water solubility through the attachment of a chiral peptide,^{7,8,18} biosensors for CA were designed to avoid the incorporation of tetrahedral stereocenters. Parent cryptophane-A is chiral, with D_3 symmetry, ³⁵ as the top and bottom cyclotrivenatrylene moieties are oriented in an *anti* configuration. With the original biotin-labeled Xe biosensor, the use of chiral peptide and maleimide functionalized biotin generated four diastereomers,⁸ which was later reduced to two diastereomers through direct coupling of the biotin to an orthogonally protected lysine residue.¹⁸ In each case, avidin binding typically produced numerous overlapping, and correspondingly broadened resonances. In targeting CA, biosensors were modeled into CAII and structures were identified that allowed coordination of the sulfonamidate anion to the active-site Zn^{2+} . We designed relatively low molecular weight biosensors (1372–1423 g/mol, not including Xe), in order to maximize rotational mobility, and achieve narrow hyperpolarized ^{129}Xe NMR resonances. Scheme 1 shows cryptophanes attached via triazole linkers with 6-, 7-, and 8-bonds to benzenesulfonamide (**C6B**, **C7B**, **C8B**). The shortest biosensor, **C6B** fit inside the protein cleft and positioned the cryptophane edge at the protein surface, approximately 15 Å from the Zn^{2+} active site. Longer biosensors **C7B** and **C8B** were conceived in order to modulate the interaction between the protein and cryptophane, and observe the resulting changes in ^{129}Xe NMR chemical shift. Modeling studies were validated by the X-ray crystal structure determination of **C8B**-CAII (Protein Data Bank accession code 3CYU, Figure 1), which used anomalous scattering information to confirm the encapsulation of Xe within the cryptophane.²⁹

Benzenesulfonamide was *para* substituted with azido-functionalized linkers **2–4** that were readily synthesized from the amine analogues (see Supporting Information, Synthetic Methods), and provided a variable 6–8 bond spacer between the cryptophane and benzenesulfonamide recognition unit. As seen in Scheme 1, linkers **2–4** were reacted with tripropargyl cryptophane (**1**) by a copper (I)-catalyzed [3+2] cycloaddition process previously developed by others,^{36,37} and applied by our lab.^{16,17} It was determined that **2** was degraded with light when dissolved in DMSO, thus conjugate **6** was successfully synthesized in the absence of light. Conjugates **7** and **8** did not require this additional precaution.

Compounds **6–8** exhibited poor solubility in aqueous media. To enable subsequent solution NMR and crystallography experiments, two carboxylic acid groups were attached to the cryptophane. 3-Azidopropionic acid **5** was readily prepared following literature protocols,³⁸ and reacted in 5-fold excess with the two remaining alkynes by the same copper (I)-catalyzed [3+2] cycloaddition process. In neutral aqueous solutions, the dianionic biosensors **C6B**-**C8B** exhibited favorable solubility for X-ray crystallography studies with CAII.

Biosensor binding studies

Initial binding studies were conducted using a dansylamide displacement assay,^{27,28} which confirmed biosensor binding to the active sites of CA I and II in solution (data not shown). Isothermal titration calorimetry was used to determine the affinity of binding of **4**, **C6B**, **C7B**, and **C8B** to CA I and II (Figure 2 and Table 1). Biosensor **C8B** exhibited higher affinity for CAII than the other compounds. However, all four compounds bound slightly better to CAI, with **C6B** exhibiting the highest affinity for CAI and five-fold discrimination over CAII. Further discrimination may be possible by varying the linker joining benzenesulfonamide and cryptophane, based on small differences between the isozymes in active-site architecture.^{39, 40} Data in Table 1 indicate that the cryptophane and tether length had little effect on the CA I and II dissociation constants ($K_d = 20\text{--}110\text{ nM}$) for this range of linkers. Larger refined thermal (B) factors for **C8B** ($\langle B \rangle = 42\text{ \AA}^2$) compared with the overall CAII model ($\langle B \rangle_{\text{main chain}} = 31\text{ \AA}^2$; $\langle B \rangle_{\text{side chain}} = 35\text{ \AA}^2$) reflect the mobility and conformational heterogeneity of the bound biosensor.²⁹ Indeed, the cryptophane in **C8B** sits a few angstroms above the active-site cleft, and there are few hydrogen bonds or other specific interactions with the protein. These structural data are consistent with the relative insensitivity of affinity to tether length. A more detailed investigation into the thermodynamics of the biosensor-protein interaction will be reported in due course.

Hyperpolarized ^{129}Xe NMR spectroscopy

As expected, the racemic mixture of unbound M_0M_0 and P_0P_0 enantiomers produced a single isotropic peak for **C6B** (63.5 ppm), **C7B** (63.9 ppm), and **C8B** (62.9 ppm) in their hyperpolarized ^{129}Xe NMR spectra (Figures 3a, 3d, 3g and Table 2).²⁰ In the presence of substoichiometric CA, the ^{129}Xe NMR peak corresponding to unbound biosensor was typically shifted 0.2–0.4 ppm downfield, which reflects differences in solution properties.

Trials with the three biosensors demonstrated repeatable and significant changes in ^{129}Xe NMR chemical shift upon addition of CA I or II. Addition of CAI to **C8B** gave an unbound resonance at 63.3 ppm and two peaks at 67.9 ppm and 66.3 ppm for the bound enantiomers (Figure 3h), with $\Delta\delta$ equal to 4.6 and 3.0 ppm. The spectrum of **C8B** with CAII (Figure 3i) gave an unbound resonance at 63.2 ppm and also showed two resonances for the bound cryptophane enantiomers, with the first at 68.2 ppm ($\Delta\delta = 5.0\text{ ppm}$) and the second at 66.9 ppm ($\Delta\delta = 3.7\text{ ppm}$). The difference between the peaks observed for **C8B** when bound to CAI (1.5 ppm) and CAII (1.3 ppm) are at the upper bound of the values observed by Lowery et al. for the diastereomeric biotin-labeled cryptophanes bound to avidin.¹⁸ The paired resonances observed for **C8B** are also likely diastereomeric in nature, based on differences in the chiral potential of ^{129}Xe in the two enantiomers bound to the chiral protein. The protein crystal structure identifies one possible site of interaction between **C8B** and CAII, with the M_0M_0 and P_0P_0 enantiomers occupying very similar positions around a central xenon atom.²⁹

Interestingly, the laser-polarized ^{129}Xe NMR spectrum of **C6B** with CAI (Figure 3b) showed only a single peak for bound cryptophane biosensor at 69.2 ppm with the unbound peak at 63.7 ppm ($\Delta\delta = 5.5\text{ ppm}$). The spectrum of **C6B** with CAII (Figure 3c) also showed a single peak for bound cryptophane, at 68.2 ppm, with the unbound peak at 63.1 ppm ($\Delta\delta = 5.1\text{ ppm}$). Based on previous results with biotin-labeled biosensors, it was expected that the short linker of **C6B** would cause a strong binding-induced shift on the encapsulated ^{129}Xe resonance due to the proximity of the biosensor to the protein.¹⁸ It was not expected, however, that **C6B** bound to CA I or II would exhibit only a single bound ^{129}Xe resonance. Diastereomerically resolved resonances were previously identified in Lowery's biotin-linked cryptophanes, and were also observed in **C8B**-CA. It is not possible that only a single enantiomer of **C6B** is binding CA, based on the stoichiometries obtained from ITC measurements (see Supporting Information, Figure S2). These data and the relatively narrow ($40 \pm 10\text{ Hz}$) ^{129}Xe @**C6B**-CA linewidth,

indicate that the two enantiomers of **C6B** must induce the same change in the potential of the ^{129}Xe nucleus when bound to the chiral protein pocket. In addition to the single “bound” peak, the short linker of **C6B** provides significantly larger chemical shift changes compared to the previous biosensors that targeted avidin,¹⁸ without sacrificing linewidth.

The laser-polarized ^{129}Xe NMR spectrum of **C7B** with CAI (Figure 3e) also showed only a single peak for bound cryptophane biosensor at 66.9 ppm with the unbound peak at 63.7 ppm ($\Delta\delta = 3.2$ ppm). Most interestingly, when complexed with CAII (Figure 3f), **C7B** showed a bound resonance at 67.0 ppm, and a second bound resonance at 71.2 ppm ($\Delta\delta = 7.5$ ppm, relative to the unbound resonance at 63.7 ppm). This shift is the largest ever reported for a xenon biosensor. Moreover, the peak at 71.2 ppm for **C7B**-CAII clearly provides isozyme discrimination between CA I and II, which creates opportunities for ^{129}Xe NMR multiplexing experiments.

The observation of a single “bound” peak for **C6B**-CAI, **C6B**-CAII, and **C7B**-CAI (Table 2) suggests that this is a common feature of xenon biosensors when the cryptophane is confined by a rigid linker within the CA environment. The cryptophane in close proximity to CA will be partially desolvated and experience a lower dielectric environment,²⁹ but is not expected to bind to the protein surface. The net environmental changes felt by the xenon in this case appear to dominate the observed ^{129}Xe NMR chemical shift, and outweigh diastereomeric considerations.

To try to explain the spectral differences between **C7B**-CAI (one “bound” peak) and **C7B**-CAII (two “bound” peaks), we inspected the two isozymes. CA I and II were calculated using EMBOSS-Align:Needle to have high sequence identity (60%) and sequence similarity (72%).⁴¹ Structural homology (r.m.s.d. = 0.92 Å) was calculated using the TOP3D program of the CCP4 package,⁴² with ligand-free crystal structures for CAI (Protein Data Bank accession code 2CAB),⁴³ and CAII (Protein Data Bank accession code 2CBA).⁴⁴ CA I and II possess active-site clefts of virtually identical width (15 Å) and depth (15 Å).⁴⁰ Thus, the 10-Å diameter cryptophane experiences similar steric environments in the two CA isozymes.

Despite these structural similarities, the cavities of CA I and II vary considerably in the distribution of polar and nonpolar residues. For example, two hydrophobic patches that are unique to the CAII active-site channel previously guided the synthesis of high-affinity enzyme inhibitors.⁴⁵ These patches, and other sites rich in aromatic residues, are accessible to the Zn^{2+} -bound cryptophane biosensor and may serve to discriminate between the enantiomers of **C7B**. We hypothesize that in **C7B**-CAI, the bound enantiomers produce equivalent ^{129}Xe NMR resonances by being in close proximity to the protein environment, whereas in **C7B**-CAII, cryptophane interactions with the protein surface lead to diastereomerism. The variation in ^{129}Xe NMR chemical shift observed for the two enantiomers of **C7B**-CAII ($\Delta\delta = 4.2$ ppm) compared to **C8B**-CAII ($\Delta\delta = 1.3$ ppm) may be due to conformational differences between the two biosensors. In **C7B**, the benzenesulfonamide is kinked by 109° relative to the linker, which may enforce interactions of one or both enantiomers with the protein surface.

Importantly for biosensing applications, the linewidths of “bound” xenon biosensors (23–50 Hz) were only somewhat broadened compared to free xenon in solution (12 ± 1 Hz) and were relatively unchanged from the “free” xenon biosensors **C7B** (27 ± 1 Hz) and **C8B** (25 ± 3 Hz). The apparently broader linewidth of **C6B** (79 ± 20 Hz) was likely the result of poor mixing and low cryptophane-bound hyperpolarized ^{129}Xe NMR signal. All three biosensors exhibit excellent solubility in aqueous solutions. In the crystal structure of **C8B**-CAII,²⁹ the enantiomers appear to interact very little with the CAII surface, which should allow rotational and translational motions of the biosensor, and promote narrow NMR linewidths. Furthermore, because the cryptophane in **C8B**-CAII appears to be unperturbed by the protein,²⁹ the xenon

within the cryptophane can continue to behave isotropically. This should make the noncovalently bound ^{129}Xe nucleus fairly insensitive to the larger rotational correlation time of the biosensor-CA complex. By comparison, the previous use of polypeptide solubilizing moieties and linkers in biotin-functionalized biosensors may have promoted binding interactions with avidin that contributed to line-broadening.¹⁸ The CA data support the design of minimally chiral, low molecular weight ^{129}Xe biosensors that target proteins with single binding sites, and also minimize binding interactions between the cryptophane and linker with the protein surface.

Discussion

In cancer patients, tumors can exist for long periods in a dormant, asymptomatic state before diagnosis and development of disease.⁴⁶ Furthermore, human cancers are characterized by the over-expression of many different proteins.⁴⁷ Thus, the ability to detect the overexpression of multiple protein biomarkers that colocalize and identify a population of abnormal cells has the potential to improve vastly the accuracy and efficacy of early cancer detection.

Towards this goal, we have shown that water-soluble ^{129}Xe NMR biosensors can be targeted with nanomolar affinity to biomedically relevant proteins, human carbonic anhydrases I and II. A xenon-binding tri-propargyl cryptophane was functionalized in two facile copper (I)-catalyzed [3+2] cycloaddition steps, where the linker to benzenesulfonamide was varied between 6 and 8 bonds. X-ray crystal structure analysis of CAII complexed with **C8B** confirmed ligation of the sulfonamide moiety to Zn^{2+} in the CA active site, with the cryptophane at the upper rim of the active-site cleft. CA is the first monomeric, single-binding-site protein that has been studied with a xenon biosensor. ITC measurements revealed that **C6B**, **C7B**, and **C8B** exhibit similar dissociation constants for CA as the bare linker **4**, indicating that the cryptophane has little effect on CA binding affinity for this range of linkers.

CA serves as a useful model system for studying xenon biosensor-protein interactions. In order to improve detection sensitivity, it has been proposed to use the HyperCEST technique,^{48, 49} in order to irradiate and quench selectively the hyperpolarized ^{129}Xe NMR signal(s) corresponding to the bound species, and subsequently detect a decrease in the bulk ^{129}Xe NMR signal, based on rapid exchange between xenon populations. ^{129}Xe NMR peaks with narrow linewidths and large changes in chemical shift will facilitate selective irradiation of one or more “bound” xenon species in solution, as required for indirect detection. Additionally, well-resolved resonances will facilitate direct detection. ^{129}Xe NMR studies with **C6B**, **C7B**, and **C8B** indicated significant and reproducible downfield shifts of 5.5, 7.5, and 5.0 ppm upon binding to CA, which are considerably larger than those observed previously for ^{129}Xe biosensors targeting avidin.¹⁸ The magnitude of the shifts, relative to typical MRI field inhomogeneity of ~1 ppm, holds considerable promise for in vivo imaging studies.

Finally, isozyme discrimination was observed for all three ^{129}Xe biosensors, with a ^{129}Xe NMR chemical shift difference of ~0.5 ppm between **C6B**-CAI and **C6B**-CAII and between **C8B**-CAI and **C8B**-CAII. Significantly, a peak was observed exclusively for **C7B**-CAII that was 4.3 ppm downfield from the single bound resonance for **C7B**-CAI. Isozyme-specific chemical shifts clearly differentiate between CA I and II, despite their homologous structures.

Conclusion

In summary, we synthesized ^{129}Xe NMR biosensors for CA I and II by modifying a cryptophane-A cage with two water-solubilizing groups and attaching an arylsulfonamide recognition moiety via a triazole linker. The linker was varied between 6 and 8 bonds, in order to tether the biosensors to active-site Zn^{2+} and modulate the interaction between cryptophane

and CA. ITC confirmed nanomolar affinity for CA I and II. When bound to CA, biosensors **C6B**, **C7B**, and **C8B** demonstrated repeatable changes in ^{129}Xe chemical shifts of 5.5, 7.5, and 5.0 ppm, with 7.5 ppm being the largest chemical shift change ever reported for a xenon biosensor. CA I and II were distinguished by **C6B** and **C8B** by reproducible 0.5 ppm chemical shift differences. Remarkably, **C7B** produced a unique resonance when bound to CAII that was shifted 4.3 ppm downfield from the resonance assigned to CAI. Based on the design principles have been advanced through this work, xenon biosensors now provide avenues for detecting diseases associated with CA and other proteins by in vivo hyperpolarized ^{129}Xe NMR spectroscopy.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by an NIH Chemical Biology Interface training grant to J.A.A., NIH grant GM49758 to D.W.C., and DOD (W81XWH-04-1-0657), NIH (1R21CA110104), and Camille and Henry Dreyfus Teacher-Scholar awards to I.J.D. We thank Ronen Marmorstein and Jeffery Saven for access to instrumentation, and Luigi Di Costanzo, George Furst, and M.G. Finn for valuable discussions. Thanks go to Kevin Jude for providing CAII, and Garry Seward and Jan-Oliver Janda for experimental assistance.

References

1. Degani H, Gusis V, Weinstein D, Feilds S, Strano S. *Nat Medicine* 1997;3:780–782.
2. Foster-Gareau P, Heyn C, Alejski A, Rutt BK. *Mag Res Med* 2003;49:968–971.
3. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. *Am J Roentgenology* 2007;188:586–592.
4. Mugler JP, et al. *Magn Reson Med* 1997;37:809–815. [PubMed: 9178229]
5. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. *Cancer Res* 2006;66:10855–10860. [PubMed: 17108122]
6. Hopkins SR, Levin DL, Emami K, Kadlecsek S, Yu J, Ishii M, Rizi RR. *J Appl Physiol* 2007;102:1244–1254. [PubMed: 17158249]
7. Spence MM, Rubin SM, Dimitrov IE, Ruiz EJ, Wemmer DE, Pines A, Yao SQ, Tian F, Schultz PG. *Proc Natl Acad Sci USA* 2001;98:10654–10657. [PubMed: 11535830]
8. Spence MM, Ruiz EJ, Rubin SM, Lowery TJ, Winssinger N, Schultz PG, Wemmer DE, Pines A. *J Am Chem Soc* 2004;126:15287–15294. [PubMed: 15548026]
9. Raftery D. *Annu Rep NMR Spectros* 2006;57:205–270.
10. Ruset IC, Ketel S, Hersman FW. *Phys Rev Lett* 2006;96:053002. [PubMed: 16486926]
11. Albert MS, Cates GD, Driehuys B, Happer W, Saam B, Springer CS, Wishnia A. *Nature* 1994;370:199–201. [PubMed: 8028666]
12. Cherubini A, Bifone A. *Prog Nuc Magn Res Spec* 2003;42:1–30.
13. Driehuys B, Cofer GP, Pollaro J, Mackel JB, Hedlund LW, Johnson GA. *Proc Natl Acad Sci USA* 2006;103:18278–18283. [PubMed: 17101964]
14. Hilty C, Lowery TJ, Wemmer DE, Pines A. *Angew Chem-Int Ed* 2006;45:70–73.
15. Seward GK, Wei Q, Dmochowski IJ. *Bioconjug Chem*. 200810.1021/bc8002265
16. Hill PA, Wei Q, Eckenhoff RG, Dmochowski IJ. *J Am Chem Soc* 2007;129:9262–9263. [PubMed: 17616197]
17. Wei Q, Seward GK, Hill PA, Patton B, Dimitrov IE, Kuzma NN, Dmochowski IJ. *J Am Chem Soc* 2006;128:13274–13283. [PubMed: 17017809]
18. Lowery TJ, Garcia S, Chavez L, Ruiz EJ, Wu T, Brotin T, Dutasta JP, King DS, Schultz PG, Pines A, Wemmer DE. *Chembiochem* 2006;7:65–73. [PubMed: 16342304]

19. Mynar JL, Lowery TJ, Wemmer DE, Pines A, Frechet JMJ. *J Am Chem Soc* 2006;128:6334–6335. [PubMed: 16683795]
20. Ruiz EJ, Sears DN, Pines A, Jameson CJ. *J Am Chem Soc* 2006;128:16980–16988. [PubMed: 17177449]
21. Krishnamurthy VM, Kaufman GK, Urbach AR, Gitlin I, Gudiksen KL, Weibel DB, Whitesides GM. *Chem Rev* 2008;108:946–1051. [PubMed: 18335973]
22. Supuran CT, Scozzafava A. *Bioorg Med Chem* 2007;15:4336–4350. [PubMed: 17475500]
23. Pastorekova S, Parkkila S, Zavada J. *Adv Clin Chem* 2006;42:167–216. [PubMed: 17131627]
24. Kaneta S, Ishizuki S, Kasahara M, Nagao S, Takahashi H. *Exper Animals* 1999;48:161–169.
25. Greer J, Erickson JW, Baldwin JJ, Varney MD. *J Med Chem* 1994;37:1035–1054. [PubMed: 8164249]
26. Supuran CT. *Nature Rev Drug Discovery* 2008;7:168–181.
27. Chen RF, Kernohan JC. *J Biol Chem* 1967;242:5813–5823. [PubMed: 4990698]
28. Nair SK, Elbaum D, Christianson DW. *J Biol Chem* 1996;271:1003–1007. [PubMed: 8557623]
29. Aaron JA, Chambers JM, Jude KM, Di Costanzo L, Dmochowski IJ, Christianson DW. *J Am Chem Soc*. 200810.1021/ja802214x
30. Wiseman T, Williston S, Brandts JF, Lin LN. *Anal Biochem* 1989;179:131–137. [PubMed: 2757186]
31. Fisher HF, Singh N. *Meth Enzymol* 1995;259:194–221. [PubMed: 8538455]
32. Walter DK, Griffith WM, Happer W. *Phys Rev Lett* 2001;86:3264–3267. [PubMed: 11327946]
33. Kuzma NN, Patton B, Raman K, Happer W. *Phys Rev Lett* 2002;88:147602. [PubMed: 11955177]
34. Jameson CJ, Jameson AK, Cohen SM. *J Chem Phys* 1973;59:4540–4546.
35. Collet A. *Comp supramol chem* 1996;2:325–365.
36. Tornøe CW, Christensen C, Meldal M. *J Org Chem* 2002;67:3057–3064. [PubMed: 11975567]
37. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem-Int Ed* 2002;41:2596–2599.
38. Leffler JE, Temple RD. *J Am Chem Soc* 1967;89:5235–5246.
39. Turkmen H, Durgun M, Yilmaztekin S, Emul M, Innocenti A, Vullo D, Scozzafava A, Supuran CT. *Bioorg Med Chem Lett* 2005;15:367–372. [PubMed: 15603956]
40. Srivastava DK, Jude KM, Banerjee AL, Halder M, Manokaran S, Kooren J, Mallik S, Christianson DW. *J Am Chem Soc* 2007;129:5528–5537. [PubMed: 17407288]
41. Rice P, Longden I, Bleasby A. *Trends Genet* 2000;16:276–277. [PubMed: 10827456]
42. CCP4 Collaborative Project. *Acta Crystallogr* 1994;D50:760–763.
43. Kannan KK, Ramanadham M, Jones TA. *Ann NY Acad Sci* 1984;429:49–60. [PubMed: 6430186]
44. Hakansson K, Carlsson M, Svensson LA, Liljas A. *J Mol Biol* 1992;227:1192–1204. [PubMed: 1433293]
45. Jain A, Whitesides GM, Alexander RS, Christianson DW. *J Med Chem* 1994;37:2100–2105. [PubMed: 8027991]
46. Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, Berger R, Hutchinson L, Naumov GN, Bender E, Akslen LA, Achilles EG, Folkman J. *FASEB J* 2006;20:947–949. [PubMed: 16638967]
47. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Henry F, Frierson J, Hampton GM. *Proc Natl Acad Sci USA* 2003;100:3410–3415. [PubMed: 12624183]
48. Schroder L, Lowery TJ, Hilty C, Wemmer DE, Pines A. *Science* 2006;314:446–449. [PubMed: 17053143]
49. Garcia S, Chavez L, Lowery TJ, Han SI, Wemmer DE, Pines A. *J Magn Reson* 2007;184:72–77. [PubMed: 17046295]

Figure 1.

Crystal structure showing **C8B**-Xe-CAII interactions.²⁹ The Xe atom (green) is shown with a van der Waals diameter of 4.3 Å, the Zn²⁺ ion is gray, the CAII backbone and surface are tan, and the M₀M₀ enantiomer of **C8B** is shown in black (carbon), red (oxygen), and blue (nitrogen), surrounded by its van der Waals surface (dots). **C8B** binds in the active site with the sulfonamidate anion coordinated to Zn²⁺.

Figure 2. Representative ITC experiment with enthalpograms for CA:biosensor complexation at 298 K in 50 mM Tris buffer, pH = 8.0. (left) CAI (14.2 μM) titrated with C8B (135.7 μM); (right) CAII (14.9 μM) titrated with C8B (200.0 μM).

Figure 3.

Laser-polarized ^{129}Xe NMR spectra with biosensors in 50 mM Tris, pH = 8.0, buffer solution. (a,d,g) ^{129}Xe NMR spectra showing individual biosensors free in solution, (b,e,h) ^{129}Xe NMR spectra showing each biosensor bound to CAI. (c,f,i) ^{129}Xe NMR spectra showing each biosensor bound to CAII. (a) **C6B** alone ($96\ \mu\text{M}$); (b) **C6B** ($188\ \mu\text{M}$) and CAI ($141\ \mu\text{M}$); (c) **C6B** ($148\ \mu\text{M}$) and CAII ($123\ \mu\text{M}$); (d) **C7B** alone ($186\ \mu\text{M}$); (e) **C7B** ($136\ \mu\text{M}$) and CAI ($100\ \mu\text{M}$); (f) **C7B** ($132\ \mu\text{M}$) and CAII ($105\ \mu\text{M}$); (g) **C8B** alone ($121\ \mu\text{M}$); (h) **C8B** ($189\ \mu\text{M}$) and CAI ($141\ \mu\text{M}$); (i) **C8B** ($189\ \mu\text{M}$) and CAII ($153\ \mu\text{M}$).

Scheme 1.

Synthesis of tri-functionalized cryptophane biosensors **C6B-C8B**, M_oM_o enantiomers shown. Reagents and conditions for two functionalization steps: (a) Sulfonamide linker (1.1 eq), 100 mM CuSO_4 (0.25 eq), 2,6-lutidine (0.25 eq), 300 mM sodium ascorbate (0.75 eq) 10:1 DMSO: H_2O , 4 h, 41 – 57% yield; (b) **5** (10 eq), 100 mM CuSO_4 (0.25 eq), 2,6-lutidine (0.25 eq), 300 mM sodium ascorbate (0.75 eq), 10:1 DMSO: H_2O , 12 h, 41 – 63% yield (17 – 36 % overall yield, as shown, from tripropargyl cryptophane, and 0.8 – 1.8% overall yield from starting materials).¹⁶

Table 1

Dissociation constants for CA-linker and CA-biosensor complexes at 298K.

Enzyme	Ligand	K_d (nM)
CAI	4	30 ± 10
	C6B	20 ± 10
	C7B	80 ± 10
	C8B	30 ± 20
CAII	4	100 ± 10
	C6B	100 ± 20
	C7B	110 ± 30
	C8B	60 ± 20

Table 2

¹²⁹Xe NMR chemical shifts for **C6B**, **C7B**, **C8B** free in solution, bound to CA I or II.

Biosensor	Unbound [ppm]	CAI [ppm] Unbound; Bound	$\Delta\delta$ CAI [ppm]	CAII [ppm] Unbound; Bound	$\Delta\delta$ CAII [ppm]
C6B	63.5	63.7; 69.2	5.5	68.2; 63.1	5.1
C7B	63.9	63.7; 66.9	3.2	*; 67.0, 71.2	3.3, 7.5
C8B	62.9	63.3; 67.9, 66.3	4.6, 3.0	63.2; 68.2, 66.9	5.0, 3.7

* A slight excess of CAII in solution led to the loss of the unbound signal.